Regulation of Fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen

被引:65
作者
Mor, G
Kohen, F
Garcia-Velasco, J
Nilsen, J
Brown, W
Song, J
Naftolin, F
机构
[1] Yale Univ, Sch Med, Dept Obstet & Gynecol, New Haven, CT 06520 USA
[2] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel
关键词
FasL; estrogen; tamoxifen; breast cancer;
D O I
10.1016/S0960-0760(00)00081-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
During neoplastic growth and metastasis, the immune system responds to the tumor by developing both cellular and humoral immune responses. In spite of this active response, tumor cells escape immune surveillance. We previously showed that FasL expression by breast tumor plays a central role in the induction of apoptosis of infiltrating Fas-immune cells providing the mechanism for tumor immune privilege. In the present study, we showed that FasL in breast tissue is functionally active, and estrogen and tamoxifen regulate its expression. We identified an estrogen recognizing element like-motif in the promoter region of the FasL gene, suggesting direct estrogen effects on FasL expression. This was confirmed by an increase in FasL expression in both RNA and protein levels in hormone sensitive breast cancer cells treated with estradiol. This effect is receptor mediated since tamoxifen blocked the estrogenic effect. Interestingly, tamoxifen also inhibited FasL expression in estrogen-depleted conditions. Moreover, an increase in FasL in breast cancer cells induces apoptosis in Fas bearing T cells and, tamoxifen blocks the induction of apoptosis. These studies provide evidence that tamoxifen inhibits FasL expression, allowing the killing of cancer cells by activated lymphocytes. This partially explains the protective effect of tamoxifen against breast cancer. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:185 / 194
页数:10
相关论文
共 59 条
  • [1] Bechmann I, 1999, GLIA, V27, P62, DOI 10.1002/(SICI)1098-1136(199907)27:1<62::AID-GLIA7>3.0.CO
  • [2] 2-S
  • [3] A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION
    BELLGRAU, D
    GOLD, D
    SELAWRY, H
    MOORE, J
    FRANZUSOFF, A
    DUKE, RC
    [J]. NATURE, 1995, 377 (6550) : 630 - 632
  • [4] BERGELSON LD, 1993, CLIN INVESTIGATOR, V71, P590
  • [5] ESTROGEN-RESPONSIVE ELEMENT OF THE HUMAN PS2 GENE IS AN IMPERFECTLY PALINDROMIC SEQUENCE
    BERRY, M
    NUNEZ, AM
    CHAMBON, P
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (04) : 1218 - 1222
  • [6] Regulation of the proinflammatory effects of Fas ligand (CD95L)
    Chen, JJ
    Sun, YN
    Nabel, GJ
    [J]. SCIENCE, 1998, 282 (5394) : 1714 - 1717
  • [7] CHEN X, 1977, J GENETIC VIROLOL, V78, P3277
  • [8] JUN-B DIFFERS IN ITS BIOLOGICAL PROPERTIES FROM, AND IS A NEGATIVE REGULATOR OF, C-JUN
    CHIU, R
    ANGEL, P
    KARIN, M
    [J]. CELL, 1989, 59 (06) : 979 - 986
  • [9] THE C-FOS PROTEIN INTERACTS WITH C-JUN/AP-1 TO STIMULATE TRANSCRIPTION OF AP-1 RESPONSIVE GENES
    CHIU, R
    BOYLE, WJ
    MEEK, J
    SMEAL, T
    HUNTER, T
    KARIN, M
    [J]. CELL, 1988, 54 (04) : 541 - 552
  • [10] NOVEL ESTROGEN RESPONSE ELEMENTS IDENTIFIED BY GENETIC SELECTION IN YEAST ARE DIFFERENTIALLY RESPONSIVE TO ESTROGENS AND ANTIESTROGENS IN MAMMALIAN-CELLS
    DANA, SL
    HOENER, PA
    WHEELER, DA
    LAWRENCE, CB
    MCDONNELL, DP
    [J]. MOLECULAR ENDOCRINOLOGY, 1994, 8 (09) : 1193 - 1207